Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In

October 29, 2026 - 14:24

A top federal health official advocated for a significant shift in medication policy regarding hormone replacement therapies while maintaining a substantial financial stake in a company that stands to gain from the change, according to newly surfaced records.

Alicia Jackson endorsed the policy revision at the Food and Drug Administration even as she held at least $115,000 in stock in a business that provides access to menopause treatments. The timing and nature of her involvement have drawn sharp criticism from government ethics specialists, who argue the situation represents a clear breach of conflict of interest standards.

The policy change in question concerns the regulatory approach to hormone replacement therapies, a category of treatment that has seen fluctuating guidance over the years. Jackson's public support for the shift came during her tenure at the agency, a period when her personal investment portfolio included holdings directly tied to the outcome of the decision.

Ethics experts described her endorsement as an obvious conflict of interest, noting that officials are generally expected to recuse themselves from matters affecting their personal financial interests. The situation raises questions about disclosure practices and the adequacy of existing safeguards meant to prevent officials from influencing policy that could enrich them personally.

The stock holding, valued at a minimum of $115,000, was not publicly highlighted at the time of her advocacy. Details of the financial entanglement emerged through subsequent review of financial disclosures and policy records. The company in which Jackson holds stock focuses on expanding access to menopause-related treatments, a market segment that would benefit directly from looser restrictions on hormone therapies.

Watchdog groups have pointed to the case as an illustration of gaps in the oversight system, arguing that current rules may not go far enough in preventing officials from weighing in on policies that align with their investment interests. Calls for tighter disclosure requirements and more rigorous recusal enforcement have followed the revelations.